Multiple myeloma is among the most serious and well-established Agent Orange presumptive conditions under 38 CFR § 3.309(e). Veterans receive 100% VA disability ($3,737.85/month) during active treatment. Bone pain, kidney disease, peripheral neuropathy, and anemia from myeloma treatment can each be separately rated — pushing combined ratings well above 100% equivalent compensation for severely affected veterans.
Multiple myeloma (ICD-10: C90.0) is a cancer of plasma cells — a type of white blood cell found in bone marrow. Myeloma causes plasma cells to multiply uncontrollably, crowding out healthy blood cells and producing abnormal proteins (M-proteins) that damage organs, particularly the kidneys. The characteristic CRAB criteria — hyperCalcemia, Renal impairment, Anemia, Bone lesions — define active myeloma requiring treatment.
Multiple myeloma is a systemic disease affecting bone marrow throughout the body. Treatment typically involves induction chemotherapy (bortezomib-based, lenalidomide-based, or daratumumab-based regimens), followed by autologous stem cell transplantation (ASCT) in eligible patients, and long-term maintenance therapy. The disease is rarely cured but can be managed for years to decades with modern treatment.
Multiple myeloma is listed in 38 CFR § 3.309(e) as a presumptive service-connected condition for veterans with qualifying herbicide exposure. The research linking Agent Orange dioxin exposure to multiple myeloma is among the most robust in the occupational oncology literature, making VA adjudicators and C&P examiners particularly familiar with this connection.
Qualifying exposure locations and circumstances:
For veterans with qualifying AO exposure, 38 CFR § 3.309(e) requires VA to grant service connection for multiple myeloma without any nexus evidence. The only requirements are:
The VA cannot deny based on other causes (family history, other exposures) for AO-presumptive veterans. The presumptive is conclusive. Also check the PACT Act presumptive framework for additional coverage if you served in Southwest Asia after 1990.
Multiple myeloma is rated under 38 CFR § 4.117, Diagnostic Code 7703 (leukemia, chronic lymphocytic) — applied analogously to multiple myeloma given the lack of a specific DC. Like other malignant neoplasms, it is rated at 100% during active treatment. After the 6-month post-treatment period:
Need help with your VA claim?
Free claim review. No upfront cost. Talk to a vetted VA attorney.
Get Free Claim Help →| Status | Rating | Notes | Monthly Pay 2026 |
|---|---|---|---|
| Active treatment (any line) | 100% | Including maintenance therapy with active monitoring | $3,737.85 |
| MGUS (Monoclonal Gammopathy) | Varies | Precursor to myeloma — may not qualify as myeloma itself; consult VSO | Varies |
| Smoldering myeloma | Varies | Intermediate state; may qualify if treatment has begun | Varies |
| Post-treatment with residuals | Based on residuals | Bone disease, kidney disease, neuropathy each rated separately | Cumulative based on combined rating |
| Relapsed/refractory myeloma | 100% | Any relapse returns to 100% during re-treatment | $3,737.85 |
An important nuance: VA maintains the 100% rating during maintenance therapy (lenalidomide, bortezomib) that follows initial treatment. If you are on maintenance therapy, you are still "in treatment" under the VA's framework and should maintain the 100% rating. Do not let VA reduce your rating while you remain on maintenance chemotherapy — this is a common and incorrect reduction.
Multiple myeloma causes severe damage to multiple organ systems. These complications may persist even when the myeloma is in remission and are each separately ratable as secondary service-connected conditions under 38 CFR § 3.310:
Myeloma causes osteolytic lesions (holes in bones) that weaken the skeleton and lead to pathological fractures, compression fractures of the spine, and chronic bone pain. Each fracture site with residual limitation of motion is rated under the musculoskeletal schedule. Spinal compression fractures causing radiculopathy or neurological deficits may be rated under the spine rating schedule (DC 5235–5243) and the neurological rating schedule respectively.
Myeloma proteins (light chains) deposit in and damage the kidneys — a condition called "myeloma kidney" or cast nephropathy. Chronic kidney disease from myeloma is rated under 38 CFR § 4.115a, DC 7502–7530 based on severity:
Bortezomib (Velcade), a proteasome inhibitor used as the backbone of most myeloma regimens, causes peripheral neuropathy in 30–40% of patients — often severe and sometimes irreversible. Thalidomide and lenalidomide also cause neuropathy. These treatment-induced neuropathies are secondary to the service-connected myeloma and are rated per affected extremity under the peripheral nerve diagnostic codes.
Myeloma suppresses normal bone marrow function, causing anemia that may persist throughout treatment and beyond. Transfusion-dependent anemia is rated under DC 7700 at 30% or higher. Anemia requiring erythropoiesis-stimulating agents (ESAs) reflects significant severity.
For AO-exposed veterans: No nexus letter is required for the primary myeloma diagnosis. The presumptive is automatic under 38 CFR § 3.309(e).
For residual conditions: Bone disease, renal impairment, and peripheral neuropathy are secondary to the service-connected myeloma. A brief hematology/oncology note confirming these are complications of the myeloma or its treatment provides the necessary secondary nexus.
For PACT Act and non-AO veterans: Veterans who were exposed to burn pits or other toxic chemicals without AO exposure will need a nexus opinion linking the multiple myeloma to the specific in-service exposure. Read about PACT Act coverage to see if your service qualifies.
Veterans with advanced multiple myeloma who require assistance with daily activities, or who suffer from loss of use of extremities due to spinal cord compression from bone disease, may qualify for Special Monthly Compensation (SMC) under 38 USC § 1114. SMC provides additional monthly compensation above the 100% rate:
Read the complete guide to VA Special Monthly Compensation to understand how to qualify and apply for SMC alongside your myeloma claim.
Check the 2026 VA disability pay rates to understand the monthly value of each disability rating percentage.
Multiple myeloma claims often involve multiple residual conditions that can significantly increase your combined rating and monthly benefits. Get a free claim assessment today.
Get Free Claim Help →